Where Will Novo Nordisk Stock Be in 3 Years?

Novo Nordisk (NYSE: NVO) fell by 29% implicit the past 12 months, and that's making investors antsy astir the company's adjacent 3 years. It's wide that it won't beryllium capable to seashore connected its net from income of Ozempic.

Let's illustration retired Novo's way implicit the adjacent 3 years to spot wherever its banal volition be, fixed that investors person been dumping it recently.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

Its adjacent procreation of value nonaccomplishment programs is facing an awkward contented

Amylin is simply a pancreatic hormone that signals fullness done a antithetic way than GLP-1 (glucagon-like peptide-1), the gut hormone mimicked by semaglutide, the progressive constituent successful Wegovy and Ozempic. So, amylin could technically beryllium utilized alongside semaglutide to suppress appetite and boost value nonaccomplishment from 2 antithetic directions. And that's the premise of Novo Nordisk's adjacent procreation of value nonaccomplishment programs.

CagriSema, its campaigner that's composed of a operation of cagrilintide (an amylin analog) and semaglutide, went to the U.S. Food and Drug Administration (FDA) successful December 2025, with the reappraisal expected to reason this year. In the bull lawsuit for Novo's stock, CagriSema volition get the greenish airy from regulators and then, starting soon aft commercialization begins, it'll instrumentality capable marketplace stock to go the starring value nonaccomplishment therapy.

The occupation with the bull thesis coming to fruition is that the objective information astir the campaigner marque it hard to believe.

In an open-label signifier 3 proceedings successful 809 adults with obesity, CagriSema showed 23% value nonaccomplishment astatine 84 weeks, meaning it lagged the 25.5% for tirzepatide, the already-approved Eli Lilly (NYSE: LLY) medicine sold arsenic Zepbound. CagriSema's broadside effects were mostly mild to mean gastrointestinal complaints, truthful the miss was astir efficacy alternatively than tolerability. The main occupation is that it's a newer programme that can't evidently bushed Lilly's older programme connected efficacy based connected what's known close now.

Another programme that could enactment the bull lawsuit is Novo's amycretin, which is 1 molecule that hits aggregate receptors, successful opposition to CagriSema's attack of combining aggregate molecules to execute that goal. Amycretin's signifier 3 obesity proceedings began dosing successful February 2026 and should wrapper up successful precocious 2029.

So, by that deadline, it should beryllium wide to the marketplace whether Novo is going to beryllium capable to motorboat a highly competitory value nonaccomplishment drug, and it'll besides beryllium wide whether the pharma's upcoming entrant was a occurrence oregon not.